Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_assertion type Assertion NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_head.
- NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_provenance.
- NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_assertion evidence source_evidence_literature NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_provenance.
- NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_assertion SIO_000772 17189322 NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_provenance.
- NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_assertion wasDerivedFrom befree-20150227 NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_provenance.
- NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_assertion wasGeneratedBy ECO_0000203 NP612973.RA_8V0iSR4GncoGe1QPr7VEa2YouCxzPuWXWqOEBpEtHE130_provenance.